The drug development company focused on rare diseases last week reported financial and operating results for the quarter ending 31 March. The numbers in themselves contained no surprises. The company made a loss of C$724k vs C$46k in Q1 2015, with the increased loss pertaining largely to a lower level of revenue recognised for accounting purposes in 2016 in relation to the VIVIMIND™ license agreement with FB Health, an increase in general and administrative costs to C$988k from $719k as
16 May 2016
Countdown to D Day
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Countdown to D Day
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
16 May 2016 -
Author:
Derren Nathan -
Pages:
6
The drug development company focused on rare diseases last week reported financial and operating results for the quarter ending 31 March. The numbers in themselves contained no surprises. The company made a loss of C$724k vs C$46k in Q1 2015, with the increased loss pertaining largely to a lower level of revenue recognised for accounting purposes in 2016 in relation to the VIVIMIND™ license agreement with FB Health, an increase in general and administrative costs to C$988k from $719k as